Esperion Says ETC-1002's Phase 2 Study Met Primary Endpoint - Quick Facts

(RTTNews) - Esperion Therapeutics, Inc. (ESPR), Monday announced full results of a Phase 2 clinical study, ETC-1002-006, of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance. The study met its primary endpoint, showing that ETC-1002 significantly lowered low-density lipoprotein cholesterol or LDL-C compared to placebo by an average of 32 percent and was well tolerated.

"We continue to build on the positive results from this Phase 2 clinical study and recently initiated a large Phase 2b clinical study in statin intolerant and statin tolerant patients," said Tim Mayleben, president and chief executive officer of Esperion. The Phase 2b study will further weigh the potential of ETC-1002 in statin intolerant patients.

Esperion said the data were presented today in an oral presentation at the 2013 Scientific Sessions of the American Heart Association in Dallas. The company previously announced positive topline results from this study in June 2013.